Using novel EV-based screening systems, drugs that showed a dose-dependent suppression of the release of IL-6 and TNF-α from EV-stimulated macrophages and which alleviated EV-induced SIRS were selected. Here, TNF is linked to systemic inflammatory response syndrome.